NCT05178628

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Feb 10, 2022
Primary completion: Dec 31, 2024
Completion date: Dec 31, 2024
First posted: Jan 5, 2022
Last posted: Mar 29, 2022
Enrollment: 450
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Drugs studied

gemcitabine
paclitaxel
tinzaparin

Indications studied

Pancreatic Neoplasms
Thromboembolism

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.